{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-001044","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2022-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.025052+00:00","generated_at":"2026-06-27T18:45:07.045519+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immix Biopharma reports IMX-110 50% response rate in STS mouse study, beating standard of care","bullets":["IMX-110 as monotherapy achieved 50% response rate in first-line-therapy-resistant STS mouse study, vs 0% for doxorubicin.","Study assessed by RECIST 1.1 criteria after one cycle; funded by Immix and conducted by major STS oncology center.","IMX-110 has FDA orphan drug designation for STS and rare pediatric disease designation for rhabdomyosarcoma.","Global STS market estimated $2.9B in 2019, projected to reach $6.5B by 2030.","Prior clinical data showed median PFS of 4 months with zero drug-related severe adverse events in heavily pretreated patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-001044","json":"https://secwatch.observer/filing/0001493152-22-001044.json","markdown":"https://secwatch.observer/filing/0001493152-22-001044.md","text":"https://secwatch.observer/filing/0001493152-22-001044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222001044/0001493152-22-001044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315222001044/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:45:07.045519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}